3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
The enhanced stability of the carbacephem nucleus over the corresponding cephalosporin nucleus has allowed the synthesis of 7-arylglycyl-3-trifluoromethyl-carbacephems. These unique carbacephems possess broad spectrum activity and high stability to both plasmid and chromosomally mediated beta-lactamases.
Cook
G K
GK
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Hornback
W J
WJ
McDonald
J H
JH
Munroe
J E
JE
Snyder
N J
NJ
D001419:Bacteria / Q000187:drug effects*; D002433:Cefaclor / Q000494:pharmacology; D002511:Cephalosporins / Q000138:chemical synthesis* / Q000494:pharmacology*; D002876:Chromosomes, Bacterial; D015195:Drug Design; D004754:Enterobacter / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006193:Haemophilus influenzae / Q000187:drug effects; D007202:Indicators and Reagents; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D010957:Plasmids; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013329:Structure-Activity Relationship; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism
D002511:Cephalosporins; D007202:Indicators and Reagents; D002433:Cefaclor; D001618:beta-Lactamases